[Recanalisation of chronic total coronary occlusions - what is the evidence and which patients will benefit?]

Kambis Mashayekhi1, Heinz Joachim Büttner1

  • 1Klinik für Kardiologie und Angiologie II, Universitäts-Herzzentrum Freiburg - Bad Krozingen, Deutschland.

Insights

Percutaneous coronary intervention for chronic total occlusions (CTO-PCI) effectively relieves symptoms by reducing ischemia. While prognostic benefits are debated, CTO-PCI is indicated for symptom relief, with success rates exceeding 90% in specialized centers.

Area of Science:

  • Interventional Cardiology
  • Cardiovascular Medicine
  • Medical Devices

Background:

  • Chronic total occlusions (CTOs) present challenges in coronary artery revascularization.
  • Advancements in recanalization techniques and devices have improved percutaneous coronary intervention (PCI) success rates for CTOs.

Purpose of the Study:

  • To evaluate the evidence for CTO-PCI and identify patient subgroups who benefit most.
  • To discuss the risk/benefit ratio and optimal recanalization strategies for CTOs.

Main Methods:

  • Review of current evidence on CTO-PCI techniques and outcomes.
  • Analysis of factors influencing the risk/benefit ratio, including lesion complexity, extent of coronary artery disease, and ventricular function.
  • Discussion of escalating recanalization strategies, including antegrade and retrograde approaches.

Main Results:

  • CTO-PCI primarily offers symptom control through reduction of myocardial ischemia.
  • Prognostic benefits of successful CTO-PCI remain a subject of ongoing debate, based on observational studies.
  • High success rates (>90%) and low complication rates are achievable with retrograde techniques in specialized centers.

Conclusions:

  • The primary indication for CTO-PCI is symptom relief and reduction of myocardial ischemia.
  • Patient selection requires careful estimation of the risk/benefit ratio.
  • Advanced techniques, including retrograde approaches, enable high success rates for complex CTOs, even in multi-vessel disease.